DFX Intelligence

Data Factory

Gilead Sciences, Inc.

Office on the family office graph

This is the graph view. The full profile, with its team, deals and sources, is on Family Offices.Open the full profile →

Search this name across graphsid dfx:fo:fa93f524-0f24-4f47-8408-1436f12bdcf3

Data as of an unrecorded date (this record's last observation) from Sworn filings; Announcements. Page built Sep 20, 2026, 12:27 PM UTC and rebuilt at most every 15 minutes.

Relationships: 2
Dated events: 19
On other graphs: 0
Observed: n/a to n/a

Across DFX

This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

People

Person	Title	Role	Seniority	Family member	Current	Evidence
Andrew D. Dickinson	Executive Vice President and Chief Financial Officer	leadership	senior	n/a	yes	fact

Relationships

Employs (1)

→ Andrew D. DickinsonPersonExecutive Vice President and Chief Financial Officer
factForm 13F

Related to (1)

← Gilead Sciences FoundationFoundationShared address
inferenceForm 990-PF

Dated events

19 bookkeeping events (roster, classification and holdings changes) folded below

Show 19 bookkeeping events

First seen by DFX
Sep 12, 2026
date not stated
Gilead Sciences, Inc. files Form 13F (non_adviser_filer, $1,935,507,854 in 6 positions)
First seen by DFX
Sep 12, 2026
date not stated
Gilead Sciences, Inc.: CANDIDATE_FAMILY_OFFICE -> CANDIDATE_FAMILY_OFFICE (13F filer that is on no adviser roster and is not institutional by name: could be an SFO, a corporate treasury or a trust company)
First seen by DFX
Sep 12, 2026
date not stated
Gilead Sciences, Inc.: CANDIDATE_FAMILY_OFFICE -> NOT_FAMILY_OFFICE (13F filer that reads as a public company or corporate treasury by name)
Occurred
May 8, 2026
Gilead Sciences, Inc. reported $2,117,784,504 across 6 13(f) positions for the quarter ended 2026-03-31
Occurred
Mar 31, 2026
Gilead Sciences, Inc. reduced Xilio Therapeutics Inc 9,105,451 -> 650,389 shares ($5,829,310 -> $5,469,771)
Occurred
Feb 12, 2026
Gilead Sciences, Inc. reported $1,935,507,854 across 6 13(f) positions for the quarter ended 2025-12-31
Occurred
Dec 31, 2025
Gilead Sciences, Inc. exited Leap Therapeutics Inc (was $2,414,893, 5,319,148 shares)
Occurred
Dec 31, 2025
Gilead Sciences, Inc. exited Tango Therapeutics Inc (was $40,777,321, 4,854,443 shares)
Occurred
Dec 31, 2025
Gilead Sciences, Inc. exited Merus N V (was $42,605,417, 452,527 shares)
Occurred
Nov 13, 2025
Gilead Sciences, Inc. reported $1,791,467,184 across 9 13(f) positions for the quarter ended 2025-09-30
Occurred
Sep 30, 2025
Gilead Sciences, Inc. exited Hookipa Pharma Inc (was $2,354,311, 1,875,945 shares)
Occurred
Sep 30, 2025
Gilead Sciences, Inc. increased Assembly Biosciences Inc 2,209,471 -> 4,505,391 shares ($40,035,615 -> $115,338,010)
Occurred
Aug 14, 2025
Gilead Sciences, Inc. reported $1,280,204,668 across 14 13(f) positions for the quarter ended 2025-06-30
Occurred
Jun 30, 2025
Gilead Sciences, Inc. reduced Kalaris Therapeutics Inc 723,273 -> 317,789 shares ($5,807,882 -> $848,497)
Occurred
May 13, 2025
Gilead Sciences, Inc. reported $1,181,331,731 across 14 13(f) positions for the quarter ended 2025-03-31
Occurred
Mar 31, 2025
Gilead Sciences, Inc. reduced Ikena Oncology Inc 2,008,338 -> 1,159,145 shares ($3,293,674 -> $1,483,706)
Occurred
Mar 31, 2025
Gilead Sciences, Inc. exited Allovir Inc (was $6,986,820, 16,635,286 shares)
Occurred
Mar 31, 2025
Gilead Sciences, Inc. opened a $5,807,882 position in Kalaris Therapeutics Inc (723,273 shares)
Occurred
Feb 13, 2025
Gilead Sciences, Inc. reported $1,551,148,266 across 16 13(f) positions for the quarter ended 2024-12-31

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 office address (Form 13F) · as of 2026-05-08

Andrew D. Dickinson
Executive Vice President and Chief Financial Officer · Revealable: 1 business phone (Form 13F)

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Family Offices
Canonical id: dfx:fo:fa93f524-0f24-4f47-8408-1436f12bdcf3
First observed: n/a
Last observed: n/a : not yet measured
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Gilead Sciences, Inc.

Office on the family office graph

This is the graph view. The full profile, with its team, deals and sources, is on Family Offices.Open the full profile →

Search this name across graphsid dfx:fo:fa93f524-0f24-4f47-8408-1436f12bdcf3

Data as of an unrecorded date (this record's last observation) from Sworn filings; Announcements. Page built Sep 20, 2026, 12:27 PM UTC and rebuilt at most every 15 minutes.

Person

Title

Role

Seniority

Family member

Current

Evidence

Andrew D. Dickinson

Executive Vice President and Chief Financial Officer

leadership

senior

n/a

yes

fact